Mental health startup Cerebral has inked a partnership with Alto Neuroscience to bring clinical trials for depression to patients’ homes.

When she helped start MeiraGTx Holdings in 2015, CEO Zandy Forbes wanted to find a way to precisely control the output of genes implanted in people to fix genetic disorders. In an analyst meeting Wednesday, MeiraGTx unveiled that technology.

Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.

Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.

Sotio has been on a roll lately. The quiet Czech biotech based in Prague got a massive $315 million raise last week, and now the biotech announced today that it’s joined in on a collaboration with Merck to evaluate a combo of Sotio’s lead candidate SOT101 with Merck’s PD-1 antibody Keytruda.

Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround. 

MeiraGTx has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX).